SG11201811183WA - Anti-infective heterocyclic compounds and uses thereof - Google Patents

Anti-infective heterocyclic compounds and uses thereof

Info

Publication number
SG11201811183WA
SG11201811183WA SG11201811183WA SG11201811183WA SG11201811183WA SG 11201811183W A SG11201811183W A SG 11201811183WA SG 11201811183W A SG11201811183W A SG 11201811183WA SG 11201811183W A SG11201811183W A SG 11201811183WA SG 11201811183W A SG11201811183W A SG 11201811183WA
Authority
SG
Singapore
Prior art keywords
international
uppsala
co7d
pct
heterocyclic compounds
Prior art date
Application number
SG11201811183WA
Inventor
Leif Kirsebom
Ram Shankar Upadhayaya
Raghava Reddy Kethiri
Anders Virtanen
Original Assignee
Bioimics Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioimics Ab filed Critical Bioimics Ab
Publication of SG11201811183WA publication Critical patent/SG11201811183WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/46—Phenazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/38—[b, e]-condensed with two six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/18—[b, e]-condensed with two six-membered rings
    • C07D279/20—[b, e]-condensed with two six-membered rings with hydrogen atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/18—[b, e]-condensed with two six-membered rings
    • C07D279/22—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom
    • C07D279/24—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom with hydrocarbon radicals, substituted by amino radicals, attached to the ring nitrogen atom
    • C07D279/28—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom with hydrocarbon radicals, substituted by amino radicals, attached to the ring nitrogen atom with other substituents attached to the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/06—Peri-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 1111111111111 0 11111111111111111111111111111011011110 111111111011111111111 011111 Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2017/222466 Al 28 December 2017 (28.12.2017) WIP0 I PCT (51) International Patent Classification: EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, C07D 417/12 (2006.01) C07D 513/06 (2006.01) MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, C07D 417/14 (2006.01) A61K 31/5415 (2006.01) TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, CO7D 279/20 (2006.01) A61K 31/538 (2006.01) KM, CO7D 279/28 (2006.01) A61P 31/00 (2006.01) ML, MR, NE, SN, TD, TG). CO7D 513/04 (2006.01) Published: (21) International Application Number: — with international search report (Art. 21(3)) PCT/SE2017/050697 — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of (22) International Filing Date: amendments (Rule 48.2(h)) 22 June 2017 (22.06.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 1650906-9 23 June 2016 (23.06.2016) SE (71) Applicant: BIOIMICS AB [SE/SE]; Sandstensvagen 7, 752 67 Uppsala (SE). (72) Inventors: KIRSEBOM, Leif; Vreta Strandvag 20, 755 _ 91 Uppsala (SE). UPADHAYAYA, Ram Shankar; Her- = ragsvagen 197, lgh 1203, 752 69 Uppsala (SE). KETHIRI, Raghava Reddy; H No. 227, Shri Nilaya, Karishma Hills, Subramanya Pura Post, Bangalore 560 061 (IN). VIRTA- =_ NEN, Anders; Sandstensvagen 7, 752 67 Uppsala (SE). (74) Agent: ZACCO SWEDEN AB; P.O. Box 5581, Val- hallavagen 117N, 114 85 Stockholm (SE). = (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, = = = HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, = = KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, = MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, = OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. = = = (84) Designated States (unless otherwise indicated, for every = kind of regional protection available): ARIPO (BW, GH, — GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, = UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, 1-1 (54) Title: ANTI-INFECTIVE HETEROCYCLIC COMPOUNDS AND USES THEREOF V::+ (57) : The present invention relates to heterocyclic compounds of Formula I useful as R 1 R 2 71' anti-infective agents. The present invention further relates to a method of treating an infection I el N e•1 4 --..... R x 1 „_ , N X 2 ' ',, -\"--- ' '''''' '-' .* * 1 X5 by administering such compounds, and to pharmaceutical compositions comprising such com- pounds. I I X 4*I''' R3 IN -- --- '\"- --'' '' , A , '\" ---- `• X 3 ';. l'* R 8 N (I) C
SG11201811183WA 2016-06-23 2017-06-22 Anti-infective heterocyclic compounds and uses thereof SG11201811183WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1650906 2016-06-23
PCT/SE2017/050697 WO2017222466A1 (en) 2016-06-23 2017-06-22 Anti-infective heterocyclic compounds and uses thereof

Publications (1)

Publication Number Publication Date
SG11201811183WA true SG11201811183WA (en) 2019-01-30

Family

ID=59285299

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201811183WA SG11201811183WA (en) 2016-06-23 2017-06-22 Anti-infective heterocyclic compounds and uses thereof

Country Status (13)

Country Link
US (1) US11130741B2 (en)
EP (1) EP3475277B1 (en)
JP (1) JP2019518771A (en)
KR (1) KR20190025920A (en)
CN (1) CN109641889A (en)
AU (1) AU2017279905B2 (en)
BR (1) BR112018076734A2 (en)
CA (1) CA3028347A1 (en)
IL (1) IL263651A (en)
MX (1) MX2018016339A (en)
RU (1) RU2019101646A (en)
SG (1) SG11201811183WA (en)
WO (1) WO2017222466A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020169682A1 (en) * 2019-02-19 2020-08-27 Yncrea Hauts De France Hydrazide derivatives and their specific use as antibacterial agents by controlling acinetobacter baumannii bacterium
WO2024062043A1 (en) * 2022-09-21 2024-03-28 Universiteit Antwerpen Substituted phenothiazines as ferroptosis inhibitors
CN115947671B (en) * 2022-11-21 2023-09-26 荣灿生物医药技术(上海)有限公司 Lipid compound containing urethane bond and application thereof
CN115806503A (en) * 2022-12-02 2023-03-17 中国海洋大学 Selective histone deacetylase inhibitor as well as preparation method and application thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL106170C (en) * 1955-12-23
GB812109A (en) * 1956-08-23 1959-04-15 Basf Ag Improvements in the dyeing of structures of linear aromatic polyesters
DE1160442B (en) 1959-03-18 1964-01-02 Degussa Process for the preparation of 3-trifluoromethylphenthiazines
US3082210A (en) 1959-10-29 1963-03-19 Rhone Poulenc Sa New 10-(azetidinyl-alkyl)phenthiazines
DE2214699A1 (en) * 1972-03-25 1973-09-27 Hoechst Ag Yellow-orange-red-red/violet water-insol phenoxazine or - phenthiazine dyes - for dyeing printing synthetic and semi-synthetic
FR2810318B1 (en) * 2000-06-15 2005-09-23 Laurent Galey DIAMANO-PHENOTHIAZINE DERIVATIVES
AU2003222197A1 (en) 2002-01-16 2003-09-02 The Regents Of The University Of California Inhibition of rna function
MXPA06012566A (en) 2004-04-30 2007-05-09 Bkg Pharma Aps Treatment of infectious diseases.
MX2009007235A (en) * 2007-01-05 2009-10-16 Bkg Pharma Aps Low-carbohydrate milk with original calcium.
EP2246349A1 (en) * 2009-04-20 2010-11-03 BKG Pharma ApS Treatment of infectious diseases
US8809317B2 (en) * 2011-03-29 2014-08-19 Prosetta Antiviral Inc. Antiviral compounds
JP5868955B2 (en) * 2010-04-30 2016-02-24 プロセッタ アンチバイラル インコーポレイテッド Antiviral compounds
WO2012122716A1 (en) * 2011-03-17 2012-09-20 Merck Sharp & Dohme Corp. Tetracyclic xanthene derivatives and methods of use thereof for treatment of viral diseases
CN103781481B (en) 2011-08-02 2018-12-14 亥姆霍兹慕尼黑中心-德国环境健康研究中心 (Gmbh) Selective depression of the phenothiazine derivative to MALT1 protease
CN104812394B (en) * 2012-11-26 2018-10-19 开普敦大学 Phenothiazine derivative and its phthisical purposes for the treatment of
CN103709122B (en) * 2013-11-29 2016-05-25 四川大学 Antitumor and the antifungal compound being used for the treatment of

Also Published As

Publication number Publication date
RU2019101646A (en) 2020-07-23
JP2019518771A (en) 2019-07-04
MX2018016339A (en) 2019-09-04
US20190233384A1 (en) 2019-08-01
EP3475277B1 (en) 2021-10-20
CA3028347A1 (en) 2017-12-28
EP3475277A1 (en) 2019-05-01
CN109641889A (en) 2019-04-16
KR20190025920A (en) 2019-03-12
US11130741B2 (en) 2021-09-28
IL263651A (en) 2019-01-31
AU2017279905A1 (en) 2019-01-31
RU2019101646A3 (en) 2020-07-23
AU2017279905B2 (en) 2021-10-14
BR112018076734A2 (en) 2019-03-26
WO2017222466A1 (en) 2017-12-28

Similar Documents

Publication Publication Date Title
SG11201806863WA (en) Tetracyclic pyridone compounds as antivirals
SG11201804170RA (en) Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201807913XA (en) Stabilized soluble pre-fusion rsv f proteins
SG11201805570WA (en) Systems and methods for long term transdermal administration
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201805368YA (en) Anthelmintic depsipeptide compounds
SG11201808237UA (en) Substituted indole compound derivatives as dengue viral replication inhibitors
SG11201811183WA (en) Anti-infective heterocyclic compounds and uses thereof
SG11201811230RA (en) Compositions and methods for reducing ocular neovascularization
SG11201408094YA (en) Neprilysin inhibitors
SG11201909615YA (en) Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same
SG11201809908TA (en) Stabilized glycopeptide antibiotic formulations
SG11201809830WA (en) Selective reduction of cysteine-engineered antibodies
SG11201902531QA (en) Liquid pharmaceutical composition
SG11201806267QA (en) Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose
SG11201909680UA (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
SG11201408617PA (en) Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders
SG11201810965YA (en) 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
SG11201907774VA (en) Sulfoximine glycosidase inhibitors
SG11201805001UA (en) Method of treating influenza a
SG11201901986SA (en) Process for the manufacture of a solid pharmaceutical adminstration form
SG11201407368VA (en) Drug for preventing and/or treating polycystic kidney disease
SG11201804885TA (en) Monomaleimide-functionalized platinum compounds for cancer therapy
SG11201806480UA (en) Derivatives of pyrroloimidazole or analogues thereof which are useful for the treatment of inter alia cancer